



March 27, 1992

Mr. Edward A. Greenhalgh
265-7 Regina Street North
Waterloo, Ontario
N2J 3B9

Dear Mr. Greenhalgh,


Your letter of February 27, 1992, has been referred to me as
Dr. Eric Bandle is no longer with 'Roche' Canada.

Basic research of the kind you propose is not done at 'Roche' Canada,
therefore we are returning your letter and materials.

Thank you for your interest in 'Roche' and good luck in your future
endeavours.

Yours very truly,

HOFFMANN-LA ROCHE LIMITED



Dr. med. Werner M. Enz
Group Director, Marketing
Pharmaceuticals

WE/mt

Enclosures

HCCI

HCCI Management Services Inc.

September 11, 1992

Edward A. Greenhalgh
265-7 Regina Street North
WATERLOO, Ontario
N2J 3B9

4045 Côte Vertu
Saint-Laurent
Montréal, Québec H4R 1R6
Tel. : (514) 333-3500
Fax.: (514) 331-1526

800, René-Lévesque Blvd. West
P.O. Box 6170, Station "A"
Montréal, Québec H3C 3K8
Tel. : (514) 871-5511
Fax.: (514) 871-5635

Dear Mr. Greenhalgh:

Upon reading the documentation you forwarded to me on July 31st, which illustrates your impressive educational background, I can understand your sentiments on receiving notice of a job opening at our Resco Plant for general labourer positions. I would, however, like to clarify that it is the responsibility of our Human Resources representatives to advise all our employees affected by the recent business changes of any job openings available within our organization. This gesture on our part is in no way meant to lessen the importance of our employees' qualifications, and was forwarded to all the Cambridge employees concerned.

It is a fact that our North American business orients itself towards the marketing of our product line and not in the domaine of scientific research. Therefore, we cannot sponsor the type of research project you have presented.

I have asked Mr. Jean-Pierre Kolo to contact you in the near future to assess with you if there are any other avenues that you could explore.

I am confident that your experience and perseverance will lead you to a successful career and I wish you the best of luck in your future endeavours.

Yours truly,


Alban W. Schuele
President

cc: J.P. Kolo

Roussel Canada Inc.

DONALD BUXTON
PRESIDENT

February 25, 1992

Mr. Edward A. Greenhalgh
265-7 Regina St. North
Waterloo, ON
N2J 3B9

Dear Mr. Greenhalgh:

Thank you for your note concerning your research proposal. Unfortunately, it does not fit the profile of our current research program or orientation, and we must, therefore, respond negatively.

As requested, I am returning all your documentation, and I wish you every success in finding a sponsor to fund your activities.

Sincerely,

A handwritten signature in dark ink, appearing to read "Don Buxton", written in a cursive style.

Enclosures

CIBA—GEIGY CANADA LTD.

6860 Century Avenue
Mississauga, Ontario L5N 2W5
Tel. (416) 567-3400
Fax (416) 821-0755

PHARMACEUTICALS DIVISION

Evert C. Vos, MD, PhD
Vice President
Medical Affairs and
Research & Development

CIBA—GEIGY

August 19, 1992

Mr. E.A. Greenhalgh
265-7 Regina Street North
Waterloo, ON N2J 3B9


Dear Mr. Greenhalgh,

Thank you for your letter of July 21, 1992 together with the enclosures.

I regret to have to inform you that we, ourselves, do not do basic, fundamental research in Canada. All our research, both pre-clinical and clinical, is contracted out. The projects we are engaged in are strictly in support of the Company's strategic goals. It is, therefore, not possible to budget support either in personal grant support or operational grant support for the work that you envisage to do.

Thank you for your interest in CIBA-Geigy and I wish you every success in reaching your objectives.

Yours sincerely,



ECV/bec



October 17, 1997

Mr. Edward A. Greenhalgh
265 Regina Street North
Apt. 7
WATERLOO, Ontario
N2J 3B9

Dear Mr. Greenhalgh:

A few months ago, Jack Kay forwarded to me an extensive package of information which you sent to him. Unfortunately, an inordinately heavy travel schedule has kept me out of the office and I have been unable to devote the time necessary to review your documentation.

We concur with your observation regarding the relatively low level of research by the foreign-owned multi-nationals in relationship to their sales. Currently, our own basic research interests focus on iron chelation, protease inhibition and skin regeneration. Regrettably, at this time, our limited resources do not permit us to expand outside the criteria of our current strategic planning guidelines. We recognize that some of the projects we turn down may, indeed, turn out to be winners. However, we must apply the strategy that works best for us.

Under separate cover, we are returning the information to you in the event that you have another potential investor that would find your work more directly aligned with their interests.

Best wishes for future success.

Sincerely,

A handwritten signature in cursive script, appearing to read 'Michael Spino', is written over a faint, larger version of the same signature.

Michael Spino, Pharm.D.
Sr. Vice President, Scientific Affairs

MRS/ads

c.c. J. Kay
R. Bozzato